MGTXMeiraGTx Holdings plc
MeiraGTx Holdings plc (MGTX) develops gene therapies for rare diseases, with a focus on neurodegenerative and oncologic indications. The next catalyst is Nov 8, 2026 — Q4 2023 Earnings Release, which will test the company’s financial resilience and guidance amid ongoing clinical trials.
- Revenue fell 57.8% YoY to $16.79M in Q3 2023, while net income surged to $25.10M, driven by a 149.5% net margin.
- Free cash flow remained negative at -$187.53M over the last 12 months, with shareholders’ equity at -$5.79M.
- The company is testing its ability to sustain operations through the next earnings release and key clinical data events.
The Read
MeiraGTx historically reacts to regulatory catalysts with median absolute moves of about 35%.
The schedule
- Sun8Nov
The earnings report tests whether the company can deliver consistent revenue and cash flow from its pipeline, especially after the last report showed a cash runway concern. The focus will be on guidance and margin commentary, not just the top line.
- Tue8Dec
The release of pivotal Phase 2 top-line data for AAV2-hAQP1 (RIX) will test the company's ability to demonstrate meaningful efficacy and safety signals, which could influence investor sentiment and future capital raising efforts.
- Sun17Jan
The update on the Phase 3 initiation for AAV-GAD (Parkinson's) will test the company's ability to advance its Parkinson's treatment candidate, which could impact its strategic direction and partnership opportunities.
- Sun7Feb
This report will test the company's ability to maintain cash flow and deliver updated guidance, especially with the recent regulatory milestones. The market will be looking for signs of progress in key trials and potential revenue from partnerships.
- Sun9May
The report will test the company's ability to sustain cash flow and deliver updated guidance, especially with the recent regulatory milestones. The market will be looking for signs of progress in key trials and potential revenue from partnerships.
- Sun8Aug
This report will test the company's ability to maintain cash flow and deliver updated guidance, especially with the recent regulatory milestones. The market will be looking for signs of progress in key trials and potential revenue from partnerships.
Past
- Thu13Aug
Actual outcome: Bull · $13.52 at outcome
MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 data for radiation-induced xerostomia on August 13. The earnings beat and regulatory milestone significantly boosted investor confidence in near-term commercial potential. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +97.3% from 2026-03-18 to 2026-08-14 (~3.0σ vs typical 75d vol). Target evaluation date 2026-09-14 (not yet reached as of 2026-08-14). Confidence 95%.
MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 data for radiation-induced xerostomia on August 13. The earnings beat and regulatory milestone significantly boosted investor confidence in near-term commercial potential. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +97.3% from 2026-03-18 to 2026-08-14 (~3.0σ vs typical 75d vol). Target evaluation date 2026-09-14 (not yet reached as of 2026-08-14). Confidence 95%.
- Sun9Aug
Actual outcome: Mixed · $13.51 at outcome
MGTX reported in-line EPS of -0.57, matching expectations, but the stock rose 3.8% due to positive forward guidance and strategic updates. The company provided clarity on cash runway and outlined a path to stabilization, which aligned with the bull case. The price movement reflected confidence in the long-term outlook despite the neutral earnings report.
Quarterly financials with a critical focus on cash runway following the recent Sanofi ROFN update and J&J bota-vec transaction.
- Thu25Jun
Actual outcome: Bull · $13.51 at outcome
MeiraGTx provided a favorable update regarding its Sanofi Riboswitch licensing agreement and right of first negotiation (ROFN). The market reacted positively to the advancement of this strategic partnership, as it reinforced confidence in the platform's commercial viability and potential for near-term milestone revenue, driving the stock 5% higher.
Potential execution of the Sanofi Riboswitch right of first negotiation (ROFN) or licensing milestone.
- Wed1Apr
Actual outcome: Bull · $8.97 at outcome
The stock closed above the bull target of $6.20, indicating strong investor confidence in the financing announcement and its potential to fund critical trials. Despite a short-term dip, the price rebounded, reflecting optimism about the company's strategic direction and the positive market reception to the equity raise.
Expected equity raise to fund the AAV-GAD Phase 3 trial and RIX pivotal studies. Market expects dilution, but the scale and pricing are the key variables.
- Mon30Mar
Actual outcome: Bear · $7.39 at outcome
MeiraGTx reported Q4 2025 financial results and announced an FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of radiation-induced xerostomia. Despite the positive pipeline development and an initial post-earnings jump, the stock ultimately declined 8.7% over the measurement period, likely pressured by a notable insider sale from the CEO and market digestion of the company's cash runway.
Release of fiscal year-end results with critical focus on the remaining $14.8M cash balance reported in the prior quarter.
- Tue24Mar
Actual outcome: Bull · $7.62 at outcome
MeiraGTx announced that the FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 to treat radiation-induced xerostomia alongside its Q4 and full-year 2025 financial results. The combination of this major regulatory milestone and reports of a significant earnings beat alleviated concerns over the company's cash runway and operational burn, driving the stock well past the bull target.
Annual report disclosure regarding remaining cash runway and operating burn. Given the Sep 2025 cash levels, guidance will likely confirm the immediate need for capital.
